The utility of Affibody-SPECT imaging for HER2-expressing cancers is further supported by a report on 30 breast cancer patients imaged with a [99mTc]Tc-labeled HER2 Affibody [54]. This evidence concerns the gene ERBB2 and breast carcinoma.